Drug Innovation, Prices and Health
UPF Economics and Business Working Paper No. 807
20 Pages Posted: 6 Oct 2009
Date Written: January 1, 2005
This article tries to reconcile economic-industrial policy with health policy when dealing with biomedical innovation and welfare state sustainability. Better health accounts for an increasingly large proportion of welfare improvements. Explanation is given to the welfare losses coming from the fact than industrial and health policy tend to ignore each other.
Drug's prices reflecting their relative effectiveness send the right signal to the industry - rewarding innovation with impact on quantity and quality of life - and to the buyers of health care services.
The level of drug's public reimbursement indicates the social willingness to pay of the different national health systems, not only by means of inclusion, or rejection, in the basket of services covered, but especially establishing the proportion of the price that is going to be financed publicly.
Reference pricing for therapeutic equivalents - as the upper limit of the social willingness to pay- and two-tiered co-payments for users (avoidable and inversely related with the incremental effectiveness of de drug) are deemed appropriate for those countries concerned at the same time with increasing their productivity and maintaining its welfare state. Profits drive R&D but not its location. There is no intrinsic contradiction between high productivity and a consolidated National Health Service (welfare state) as the European Nordic Countries are telling us every day.
Keywords: Biomedical R&D, Industrial Policy, Drug's Price Regulation, Health Policy, Welfare State, Health Economics
JEL Classification: D45, I18, P35, K23
Suggested Citation: Suggested Citation